E
Tonix Pharmaceuticals Holding Corp.
TNXP
$16.88
-$0.42-2.43%
E
Sell
3/27/2023Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to E+ from D- on 3/27/2023 due to a decline in the growth index, solvency index and total return index. The quick ratio declined from 10.49 to 6.61, and EBIT declined 10.6% from -$29.59M to -$32.73M.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to E+ from D- on 3/27/2023 due to a decline in the growth index, solvency index and total return index. The quick ratio declined from 10.49 to 6.61, and EBIT declined 10.6% from -$29.59M to -$32.73M.
D
Sell
3/14/2023Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 03/14/2023.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 03/14/2023.
D
Sell
2/23/2023Upgraded
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index.
D
Sell
2/8/2023Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index.
D
Sell
1/12/2023Upgraded
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 1/12/2023 due to an increase in the volatility index and total return index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 1/12/2023 due to an increase in the volatility index and total return index.
D
Sell
11/14/2022Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 11/14/2022 due to a decline in the growth index and volatility index. EBIT declined 26.8% from -$23.34M to -$29.59M, and operating cash flow declined 11.17% from -$21.17M to -$23.54M.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 11/14/2022 due to a decline in the growth index and volatility index. EBIT declined 26.8% from -$23.34M to -$29.59M, and operating cash flow declined 11.17% from -$21.17M to -$23.54M.
D
Sell
8/15/2022Upgraded
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 8/15/2022 due to an increase in the valuation index, growth index and solvency index. Operating cash flow increased 31.81% from -$31.05M to -$21.17M, earnings per share increased from -$1.6192 to -$1.2228, and EBIT increased 11.73% from -$26.44M to -$23.34M.
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 8/15/2022 due to an increase in the valuation index, growth index and solvency index. Operating cash flow increased 31.81% from -$31.05M to -$21.17M, earnings per share increased from -$1.6192 to -$1.2228, and EBIT increased 11.73% from -$26.44M to -$23.34M.
D
Sell
5/31/2022Upgraded
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D- from E+ on 05/31/2022.
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D- from E+ on 05/31/2022.
E
Sell
5/13/2022Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to E+ from D- on 5/13/2022 due to a decline in the solvency index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to E+ from D- on 5/13/2022 due to a decline in the solvency index.
D
Sell
5/5/2022Upgraded
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D- from E+ on 5/5/2022 due to an increase in the total return index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D- from E+ on 5/5/2022 due to an increase in the total return index.
E
Sell
4/20/2022Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to E+ from D- on 4/20/2022 due to a decline in the growth index and total return index. Operating cash flow declined 73.37% from -$12.95M to -$22.45M, EBIT declined 59.05% from -$18.54M to -$29.48M, and earnings per share declined from -$0.0506 to -$0.0655.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to E+ from D- on 4/20/2022 due to a decline in the growth index and total return index. Operating cash flow declined 73.37% from -$12.95M to -$22.45M, EBIT declined 59.05% from -$18.54M to -$29.48M, and earnings per share declined from -$0.0506 to -$0.0655.
D
Sell
3/15/2022Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 3/15/2022 due to a decline in the volatility index and total return index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 3/15/2022 due to a decline in the volatility index and total return index.
D
Sell
2/17/2022Upgraded
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 2/17/2022 due to an increase in the volatility index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 2/17/2022 due to an increase in the volatility index.
D
Sell
2/1/2022Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 2/1/2022 due to a decline in the volatility index and total return index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 2/1/2022 due to a decline in the volatility index and total return index.
D
Sell
1/13/2022Upgraded
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 1/13/2022 due to an increase in the volatility index and valuation index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 1/13/2022 due to an increase in the volatility index and valuation index.
D
Sell
12/29/2021Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 12/29/2021 due to a decline in the total return index and volatility index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 12/29/2021 due to a decline in the total return index and volatility index.
D
Sell
12/14/2021Upgraded
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 12/14/2021 due to an increase in the volatility index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 12/14/2021 due to an increase in the volatility index.
D
Sell
11/26/2021Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 11/26/2021 due to a decline in the volatility index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 11/26/2021 due to a decline in the volatility index.
D
Sell
11/10/2021Upgraded
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from E+ on 11/10/2021 due to an increase in the growth index and volatility index. Operating cash flow increased 32.25% from -$19.11M to -$12.95M, earnings per share increased from -$0.0711 to -$0.0506, and EBIT increased 21.34% from -$23.56M to -$18.54M.
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from E+ on 11/10/2021 due to an increase in the growth index and volatility index. Operating cash flow increased 32.25% from -$19.11M to -$12.95M, earnings per share increased from -$0.0711 to -$0.0506, and EBIT increased 21.34% from -$23.56M to -$18.54M.
E
Sell
11/8/2021Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index and volatility index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index and volatility index.
D
Sell
9/17/2021Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 9/17/2021 due to a decline in the total return index and growth index. EBIT declined 13.63% from -$20.74M to -$23.56M.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 9/17/2021 due to a decline in the total return index and growth index. EBIT declined 13.63% from -$20.74M to -$23.56M.
D
Sell
4/5/2021Upgraded
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 4/5/2021 due to an increase in the total return index and volatility index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 4/5/2021 due to an increase in the total return index and volatility index.
D
Sell
3/19/2021Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 3/19/2021 due to a decline in the growth index, volatility index and valuation index. EBIT declined 41.87% from -$12M to -$17.02M.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 3/19/2021 due to a decline in the growth index, volatility index and valuation index. EBIT declined 41.87% from -$12M to -$17.02M.
D
Sell
3/16/2021Upgraded
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 3/16/2021 due to an increase in the volatility index, total return index and valuation index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 3/16/2021 due to an increase in the volatility index, total return index and valuation index.
D
Sell
2/26/2021Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 2/26/2021 due to a decline in the volatility index and valuation index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 2/26/2021 due to a decline in the volatility index and valuation index.
D
Sell
2/9/2021Upgraded
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 2/9/2021 due to an increase in the volatility index, total return index and solvency index. The quick ratio increased from 11.76 to 12.71.
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 2/9/2021 due to an increase in the volatility index, total return index and solvency index. The quick ratio increased from 11.76 to 12.71.
D
Sell
10/14/2020Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 10/14/2020 due to a decline in the volatility index and total return index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 10/14/2020 due to a decline in the volatility index and total return index.
D
Sell
9/29/2020Upgraded
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 9/29/2020 due to an increase in the total return index and volatility index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 9/29/2020 due to an increase in the total return index and volatility index.
D
Sell
9/10/2020Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 9/10/2020 due to a decline in the volatility index and total return index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 9/10/2020 due to a decline in the volatility index and total return index.
D
Sell
8/26/2020Upgraded
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 8/26/2020 due to an increase in the volatility index, solvency index and total return index. The quick ratio increased from 11.53 to 11.76.
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 8/26/2020 due to an increase in the volatility index, solvency index and total return index. The quick ratio increased from 11.53 to 11.76.
D
Sell
8/4/2020Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 8/4/2020 due to a decline in the volatility index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to D- from D on 8/4/2020 due to a decline in the volatility index.
D
Sell
7/20/2020Upgraded
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 7/20/2020 due to an increase in the solvency index, volatility index and growth index. The quick ratio increased from 2.19 to 11.53, earnings per share increased from -$2.8575 to -$0.3739, and debt to equity declined from 0.04 to 0.01.
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D from D- on 7/20/2020 due to an increase in the solvency index, volatility index and growth index. The quick ratio increased from 2.19 to 11.53, earnings per share increased from -$2.8575 to -$0.3739, and debt to equity declined from 0.04 to 0.01.
D
Sell
4/17/2020Upgraded
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D- from E+ on 4/17/2020 due to an increase in the volatility index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D- from E+ on 4/17/2020 due to an increase in the volatility index.
E
Sell
3/30/2020Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to E+ from D- on 3/30/2020 due to a decline in the solvency index, efficiency index and growth index. The quick ratio declined from 4.24 to 2.19, net income declined 11.09% from -$7.84M to -$8.71M, and EBIT declined 10.68% from -$7.89M to -$8.73M.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to E+ from D- on 3/30/2020 due to a decline in the solvency index, efficiency index and growth index. The quick ratio declined from 4.24 to 2.19, net income declined 11.09% from -$7.84M to -$8.71M, and EBIT declined 10.68% from -$7.89M to -$8.73M.
D
Sell
2/12/2020Upgraded
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D- from E+ on 2/12/2020 due to an increase in the solvency index and efficiency index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D- from E+ on 2/12/2020 due to an increase in the solvency index and efficiency index.
E
Sell
9/7/2018Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to E+ from D- on 9/7/2018 due to a decline in the solvency index, volatility index and total return index. The quick ratio declined from 8.14 to 6.64.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to E+ from D- on 9/7/2018 due to a decline in the solvency index, volatility index and total return index. The quick ratio declined from 8.14 to 6.64.
D
Sell
6/28/2018Upgraded
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D- from E+ on 6/28/2018 due to an increase in the total return index and volatility index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D- from E+ on 6/28/2018 due to an increase in the total return index and volatility index.
E
Sell
4/17/2018Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to E+ from D- on 4/17/2018 due to a decline in the volatility index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to E+ from D- on 4/17/2018 due to a decline in the volatility index.
D
Sell
4/2/2018Upgraded
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D- from E+ on 4/2/2018 due to an increase in the volatility index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D- from E+ on 4/2/2018 due to an increase in the volatility index.
E
Sell
3/15/2018Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to E+ from D- on 3/15/2018 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 15.96 to 11.99.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to E+ from D- on 3/15/2018 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 15.96 to 11.99.
D
Sell
12/1/2017Upgraded
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D- from E+ on 12/1/2017 due to an increase in the solvency index, total return index and volatility index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was upgraded to D- from E+ on 12/1/2017 due to an increase in the solvency index, total return index and volatility index.
E
Sell
3/14/2017Downgrade
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to E+ from D- on 3/14/2017 due to a noticeable decline in the total return index, volatility index and solvency index.
Tonix Pharmaceuticals Holding Corp. (TNXP) was downgraded to E+ from D- on 3/14/2017 due to a noticeable decline in the total return index, volatility index and solvency index.
D
Sell
3/11/2016Downgrade
Tonix Pharmaceuticals Holding Corp (TNXP) was downgraded to D- from D on 3/11/2016 due to a major decline in the total return index, volatility index and efficiency index. Total capital declined 23.53% from $52.65M to $40.26M, and net income declined 0.83% from -$13.25M to -$13.36M.
Tonix Pharmaceuticals Holding Corp (TNXP) was downgraded to D- from D on 3/11/2016 due to a major decline in the total return index, volatility index and efficiency index. Total capital declined 23.53% from $52.65M to $40.26M, and net income declined 0.83% from -$13.25M to -$13.36M.
D
Sell
9/29/2015Downgrade
Tonix Pharmaceuticals Holding Corp (TNXP) was downgraded to D from D+ on 9/29/2015 due to a decline in the growth index, volatility index and efficiency index. Total capital declined 18.71% from $56.89M to $46.24M.
Tonix Pharmaceuticals Holding Corp (TNXP) was downgraded to D from D+ on 9/29/2015 due to a decline in the growth index, volatility index and efficiency index. Total capital declined 18.71% from $56.89M to $46.24M.
D
Sell
6/16/2015Upgraded
Tonix Pharmaceuticals Holding Corp (TNXP) was upgraded to D+ from D on 6/16/2015 due to a noticeable increase in the growth index, efficiency index and volatility index. Total capital increased 57.61% from $36.09M to $56.89M, operating cash flow increased 10.16% from -$8.22M to -$9.05M, and net income increased 7.7% from -$8.99M to -$9.68M.
Tonix Pharmaceuticals Holding Corp (TNXP) was upgraded to D+ from D on 6/16/2015 due to a noticeable increase in the growth index, efficiency index and volatility index. Total capital increased 57.61% from $36.09M to $56.89M, operating cash flow increased 10.16% from -$8.22M to -$9.05M, and net income increased 7.7% from -$8.99M to -$9.68M.
D
Sell
11/7/2014Downgrade
Tonix Pharmaceuticals Holding Corp (TNXP) was downgraded to D from D+ on 11/7/2014 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 14.74% from -$5.7M to -$4.86M.
Tonix Pharmaceuticals Holding Corp (TNXP) was downgraded to D from D+ on 11/7/2014 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 14.74% from -$5.7M to -$4.86M.
D
Sell
9/29/2014Downgrade
Tonix Pharmaceuticals Holding Corp (TNXP) was downgraded to D+ from C- on 9/29/2014 due to a substantial decline in the volatility index.
Tonix Pharmaceuticals Holding Corp (TNXP) was downgraded to D+ from C- on 9/29/2014 due to a substantial decline in the volatility index.
C
Hold
8/19/2014Downgrade
Tonix Pharmaceuticals Holding Corp (TNXP) was downgraded to C- from C on 8/19/2014 due to a significant decline in the efficiency index, growth index and solvency index. The quick ratio declined from 21.78 to 18.5, and total capital declined 10.91% from $48.2M to $42.94M.
Tonix Pharmaceuticals Holding Corp (TNXP) was downgraded to C- from C on 8/19/2014 due to a significant decline in the efficiency index, growth index and solvency index. The quick ratio declined from 21.78 to 18.5, and total capital declined 10.91% from $48.2M to $42.94M.
C
Hold
5/14/2014Upgraded
Tonix Pharmaceuticals Holding Corp (TNXP) was upgraded to C from D+ on 5/14/2014 due to a significant increase in the efficiency index, growth index and solvency index. Total capital increased 609.7% from $6.79M to $48.2M, the quick ratio increased from 3.71 to 21.78, and debt to equity declined from 0.04 to 0.01.
Tonix Pharmaceuticals Holding Corp (TNXP) was upgraded to C from D+ on 5/14/2014 due to a significant increase in the efficiency index, growth index and solvency index. Total capital increased 609.7% from $6.79M to $48.2M, the quick ratio increased from 3.71 to 21.78, and debt to equity declined from 0.04 to 0.01.
NASDAQ
04/11/2025 4:00PM Eastern
Quotes delayed
